menu

MENU

繁體中文

Contact Us

Menu

Menu

Company

Introduction
Team & Board of Directors
Partners
Investors
Latest News

R&D Pipeline

Overview
Intranasal Vaccines
Asthma Immunotherapy
Respiratory Antiviral Immunotherapy

Company

Introduction

Team & Board of Director

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Contact us

Latest News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form

December 8, 2020

【環球生技月刊】昱厚過敏性鼻炎藥 Ib/IIa期試驗結果：安全性佳、症狀改善過半數

Press

December 7, 2020

【公告】公告本公司研發新藥AD17002[LTh(αΚ)]屋塵蹣過敏性 鼻炎治療臨床Ib/IIa期試驗結果

Press

November 23, 2020

Advagene Collaborates with Taipei Medical University on the Research Project "Immune Regulation Mechanism of AD17002-AI in Asthma and Allergic Rhinitis."

Updates

November 23, 2020

Advagene's "Adjuvanted Intranasal Influenza Vaccine (106IDX10023)" Development Project Selected by the TFDA as a High-Potential Product and Designated as an Index Project

Updates

November 23, 2020

【公告】公告本公司「噴鼻流感佐劑疫苗(106IDX10023)」研發案件 ，獲衛福部食藥署(TFDA)評選列入諮詢輔導案件

Press